1. Austria Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Biogena Group Invest AG

Biogena Group Invest AG

VVIE:BIO
5.10
EUR
+0.05
(+0.99%)
0.07EPS
41.35P/E
12.13MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
0.17
0.08
0.06
0.04
0.09
0.09
Basic EPS, GAAP
-0.01
0.06
0.18
0.07
0.04
0.08
0.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.05
1.09
2.16
2.14
2.13
2.18
2.2
Tangible Book Value per Share
0.05
1.09
2.16
2.14
2.13
2.18
2.2
Basic Weighted Avg Shares
2
2
4
4
4
4
4
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
12.4
-22.57
37.11
2.07
53.15
51
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
1
- -
- -
- -
- -
Effective Tax Rate (%)
- -
22.72
9.97
1.17
1.99
1.05
1.19
Profit Margin (%)
- -
35.42
222.09
118.77
103.82
89.73
83.55
Working Capital
- -
- -
1
1
1
1
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
2
9
9
8
9
9
Return on Invested Capital (%)
- -
2.66
-1.26
1.07
0.04
2.24
2.01
Return on Capital (%)
- -
10.26
13.62
3.48
2.03
3.84
3.35
Return on Common Equity (%)
- -
10.26
13.62
3.48
2.03
3.84
3.35

Capital Structure

EUR

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

EUR

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
59.52%
1.08%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
101.81%
-11.19%
Sales/Revenue/Turnover
- -
11.91%
-4.62%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.08
2026
- -
- -
- -
- -
0.07

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Julia Ganglbauer
Full Time Employees
3
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Strubergasse 24 Salzburg Austria 5020
IPO Date
Nov 27, 2020
Website
biogena-investors-club.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Biogena Group Invest AG operates as a holding entity for the broader Biogena Group, which focuses on the health and wellness sector. The group's primary business involves the creation, manufacturing, and global distribution of advanced, science-backed micronutrient formulations. These premium dietary supplements adhere to a stringent pure substance principle, ensuring they are free from unnecessary additives, and are produced in Salzburg, Austria.